The North America Filgrastim Market is expected to witness market growth of 7.3% CAGR during the forecast period (2021-2027).
Filgrastim is majorly given for neutropenia that is caused by bone marrow transplantation and chemotherapy in patients. It is one of the supportive therapies used in numerous kinds of cancers. In the past few years, cancer prophylaxis has significantly increased in various developed nations and many governments have taken supportive initiatives for creating awareness and educating people about its early treatment. Thus, such aspects are estimated to propel the growth of the filgrastim market over the forecast period.
Approved biosimilars like Neukine, Colstim, Grafeel, and Filcad that are comparatively inexpensive and widely available in emerging nations, thereby augment the growth of the filgrastim market during the forecast period.
The strong healthcare system of various developed nations of this region including the US and Canada is estimated to fuel the growth of the regional filgrastim market over the forecast period. Factors like the increasing prevalence of chronic diseases and the growing geriatric populations are anticipated to augment the growth of the regional filgrastim market in the coming years.
The presence of various key market players in this region along with the increasing investment in R&D activities to develop more effective products is expected to accelerate the growth of the regional market. In addition, supportive reimbursement policies of the governments in this region, are motivating patients to get their treatment and thus, opening the growth avenues for the players operating in the regional market.
The US market dominated the North America Filgrastim Market by Country in 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $266.7 million by 2027. The Canada market is poised to grow at a CAGR of 9.7% during (2021 - 2027). Additionally, The Mexico market is is expected to showcase a CAGR of 8.7% during (2021 - 2027).
Based on Drug Type, the market is segmented into Biosimilar and Biologic. Based on Indication, the market is segmented into Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd. (Kirin Company), Cadila Healthcare Ltd. (Zydus Cadila), Apotex, Inc., and Toksöz Group
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
- Biosimilar and
- Biologic
By Indication
- Chemotherapy induced Neutropenia
- Chronic Neutropenia and
- Other Indications
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies and
- Online Pharmacies
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Amgen, Inc.
- Pfizer, Inc.
- Novartis AG
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Kyowa Kirin Co., Ltd. (Kirin Company)
- Cadila Healthcare Ltd. (Zydus Cadila)
- Apotex, Inc.
- Toksöz Group
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Companies Mentioned
- Abbott Laboratories
- Amgen, Inc.
- Pfizer, Inc.
- Novartis AG
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Kyowa Kirin Co., Ltd. (Kirin Company)
- Cadila Healthcare Ltd. (Zydus Cadila)
- Apotex, Inc.
- Toksöz Group
Methodology
LOADING...
